Cyclacel Pharmaceuticals Inc (CYCC)
1.96
+0.13
(+7.10%)
USD |
NASDAQ |
Apr 24, 10:16
Cyclacel Pharmaceuticals Free Cash Flow (Quarterly): -3.91M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -3.91M |
| September 30, 2023 | -4.036M |
| June 30, 2023 | -1.305M |
| March 31, 2023 | -6.867M |
| December 31, 2022 | -5.169M |
| September 30, 2022 | -6.968M |
| June 30, 2022 | -1.918M |
| March 31, 2022 | -6.779M |
| December 31, 2021 | -4.551M |
| September 30, 2021 | -6.219M |
| June 30, 2021 | -4.153M |
| March 31, 2021 | -3.644M |
| December 31, 2020 | -1.194M |
| September 30, 2020 | -2.179M |
| June 30, 2020 | -1.846M |
| March 31, 2020 | -2.811M |
| December 31, 2019 | -1.12M |
| September 30, 2019 | -2.015M |
| June 30, 2019 | -2.636M |
| March 31, 2019 | -3.686M |
| December 31, 2018 | -2.042M |
| September 30, 2018 | -0.725M |
| June 30, 2018 | -1.812M |
| March 31, 2018 | -2.161M |
| December 31, 2017 | -2.222M |
| Date | Value |
|---|---|
| September 30, 2017 | -1.258M |
| June 30, 2017 | -0.201M |
| March 31, 2017 | -3.812M |
| December 31, 2016 | -2.943M |
| September 30, 2016 | -2.953M |
| June 30, 2016 | -1.036M |
| March 31, 2016 | -3.147M |
| December 31, 2015 | -2.678M |
| September 30, 2015 | -4.116M |
| June 30, 2015 | -2.786M |
| March 31, 2015 | -4.914M |
| December 31, 2014 | -3.675M |
| September 30, 2014 | -6.444M |
| June 30, 2014 | -4.135M |
| March 31, 2014 | -4.757M |
| December 31, 2013 | -5.487M |
| September 30, 2013 | -2.146M |
| June 30, 2013 | -5.314M |
| March 31, 2013 | -5.46M |
| December 31, 2012 | -2.459M |
| September 30, 2012 | -2.11M |
| June 30, 2012 | -3.706M |
| March 31, 2012 | -3.78M |
| December 31, 2011 | -3.259M |
| September 30, 2011 | -2.268M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-6.968M
Minimum
Sep 2022
-1.12M
Maximum
Dec 2019
-3.648M
Average
-3.644M
Median
Mar 2021
Free Cash Flow (Quarterly) Benchmarks
| Corvus Pharmaceuticals Inc | -5.167M |
| Oragenics Inc | -1.102M |
| Relmada Therapeutics Inc | -10.25M |
| Alpine Immune Sciences Inc | -19.08M |
| MAIA Biotechnology Inc | -3.992M |